Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

por Ghasemi, R, Rapposelli, I G, Capone, E, Rossi, C, Lattanzio, R, Piantelli, M, Sala, G, Iacobelli, S
Publicado 2014

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

por De Cola, A, Volpe, S, Budani, M C, Ferracin, M, Lattanzio, R, Turdo, A, D'Agostino, D, Capone, E, Stassi, G, Todaro, M, Di Ilio, C, Sala, G, Piantelli, M, Negrini, M, Veronese, A, De Laurenzi, V
Publicado 2015

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

por Vicencio, J. M., Evans, R., Green, R., An, Z., Deng, J., Treacy, C., Mustapha, R., Monypenny, J., Costoya, C., Lawler, K., Ng, K., De-Souza, K., Coban, O., Gomez, V., Clancy, J., Chen, S. H., Chalk, A., Wong, F., Gordon, P., Savage, C., Gomes, C., Pan, T., Alfano, G., Dolcetti, L., Chan, J. N. E., Flores-Borja, F., Barber, P. R., Weitsman, G., Sosnowska, D., Capone, E., Iacobelli, S., Hochhauser, D., Hartley, J. A., Parsons, M., Arnold, J. N., Ameer-Beg, S., Quezada, S. A., Yarden, Y., Sala, G., Ng, T.
Publicado 2022